Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation

Neurology. 2018 Feb 13;90(7):309-311. doi: 10.1212/WNL.0000000000004969. Epub 2018 Jan 19.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal
  • Disease Progression
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell*
  • Multiple Sclerosis*

Substances

  • Antibodies, Monoclonal
  • Alemtuzumab